U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H28O2
Molecular Weight 312.4458
Optical Activity ( + / - )
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORGESTREL

SMILES

[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=WWYNJERNGUHSAO-XUDSTZEESA-N
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25698840

Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active. Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy. Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Originator

Approval Year

1968
62
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
Agonist
2678
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

2000
Primary
Approved
8429
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

2000
Preventing
Approved
8429
OVRETTE

Approved Use

Progestin-only oral contraceptives are indicated for the prevention of pregnancy.

Launch Date

1973
Preventing
Approved
8429
ELINEST

Approved Use

Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.2 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
14.11 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
360.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
123.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.7 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
24.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
healthy, 16-45
n = 1714
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 16-45
Sex: F
Population Size: 1714
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Disc. AE: Menstrual irregularity, Amenorrhea...
AEs leading to
discontinuation/dose reduction:
Menstrual irregularity (0.7%)
Amenorrhea (0.06%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Disc. AE: Metrorrhagia, Bleeding vaginal...
AEs leading to
discontinuation/dose reduction:
Metrorrhagia (8.7%)
Bleeding vaginal (3.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
AEs

AEs

AESignificanceDosePopulation
Bleeding 1.5%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
healthy, 16-45
n = 1714
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 16-45
Sex: F
Population Size: 1714
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
Amenorrhea 0.06%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Menstrual irregularity 0.7%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Bleeding vaginal 3.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Metrorrhagia 8.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587
substrate
1037

inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882

CYP2C8
911

CYP2B6
810

BSEP
402

MRP2
383

MRP3
157

MRP4
204
CYP1A2
1054

CYP2A6
543

CYP2C19
991

CYP2E1
667
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B3
715
 likely
BSEP
403
 no [IC50 >133 uM]
MRP2
475
 no [IC50 >133 uM]
MRP3
207
 no [IC50 >133 uM]
MRP4
238
 no [IC50 >133 uM]
CYP1A2
1692
 no [IC50 >250 uM]
CYP2A6
739
 no [IC50 >250 uM]
CYP2C19
1553
 no [IC50 >250 uM]
CYP2C9
1819
 no [IC50 >250 uM]
CYP2D6
1891
 no [IC50 >250 uM]
CYP2E1
970
 no [IC50 >250 uM]
CYP3A4
1925
 yes [IC50 13.6 uM]
CYP2B6
1001
 yes
CYP2C8
965
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
543
 likely
CYP2C9
1037
 likely
CYP2E1
667
 likely
CYP3A4
1737
 major
yes (co-administration study)
Comment: Concomitant administration of efavirenz (moderate CYP3A inducer) has been found to reduce plasma levels of levonorgestrel (AUC) by around 50%.
Page: (ClinPharm) 16-17
CYP2C19
991
 minor
CYP1A2
1054
 unlikely
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:6443
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6443
ChemicalBook
CB2752440
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2752440
ChemicalBook
CB7125746
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7125746
MolPort
MolPort-002-510-453
https://www.molport.com/shop/molecule-link/MolPort-002-510-453
Selleck Chemicals
Levonorgestrel(Levonelle)
http://www.selleckchem.com/products/Levonorgestrel(Levonelle).html
ZINC
ZINC000003814395
http://zinc15.docking.org/substances/ZINC000003814395
eMolecules
29781161
https://www.emolecules.com/cgi-bin/more?vid=29781161
eMolecules
494705
https://www.emolecules.com/cgi-bin/more?vid=494705
PubMed

PubMed

TitleDatePubMed
Nomenclature of the gonane progestins.
1999 Dec
A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
1999 May-Jun
Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding.
2000 Jul
Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH).
2000 Nov
Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression.
2000 Oct
The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review.
2001 Jan
Internet availability of contraceptives.
2001 Jan
Indigenous notions of the workings of the body: conflicts and dilemmas with Norplant use in rural Bangladesh.
2001 Jan
A progestin-releasing intrauterine device for long-term contraception.
2001 Jan 22
Long-acting delivery microspheres of levo-norgestrol-poly(3-hydroxybutyrate): their preparation, characterization and contraceptive tests on mice.
2001 Jan-Feb
Use of Norplant implants in the immediate postpartum period among asymptomatic HIV-1-positive mothers.
2001 Jul
A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies.
2001 Jul
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.
2001 Jul 21
The roles of estrogen and progestin in producing deciduosarcoma and other lesions in the rabbit.
2001 Jul-Aug
The development and regression of deciduosarcomas and other lesions caused by estrogens and progestins in rabbits.
2001 Jul-Aug
The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function.
2001 Jun
Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development.
2001 Jun
Clinical recommendations for oxcarbazepine.
2001 Mar
Preferential prescribing of type of combined oral contraceptive pill by general practitioners to teenagers with acne.
2001 Mar
Practices of prescribing oral contraceptives in Poland.
2001 Mar
Progestin regulation of galanin and prolactin gene expression in oestrogen-induced pituitary tumours.
2001 Mar
Levonorgestrel-releasing intrauterine devices.
2001 Mar 10
Levonorgestrel-releasing intrauterine devices.
2001 Mar 10
[Levonorgestrel releasing intrauterine spiral--contraception and therapeutic indications].
2001 Mar 15
[Contraception with depot gestagens].
2001 May
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
2001 May
Determination of circular dichroism and ultraviolet spectral parameters of norgestimate- and other Delta(4)-3-ketosteroid oxime isomers via normal phase HPLC method.
2001 Sep
Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women.
2001 Sep 28
Patents

Patents

20010005728
16
JP1070410A
6
JP2002338318A
4
JP2002543156A
35
JP2005500299A
34
JP2006096775A
34
JP2007524648A
4
JP2010180236A
4
JPH00673008A
4
JPH0395994A
4
JPH0437741A
4
JPS6168421A
4
JPS6470410A
6

Sample Use Guides

In Vivo Use Guide
Mirena contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to half that value after 5 years. Mirena must be removed by the end of the fifth year and can be replaced at the time of removal with a new Mirena if continued contraceptive protection is desired.
Route of Administration: Vaginal
In Vitro Use Guide
5 × 10(-5) mol/L Levonorgestrel (LNG) revealed a time-dependent inhibition of cell proliferation and an increase of apoptosis in both human endometrial stromal cells (HESCs) and glandular cells (HEGCs). Furthermore, these cells demonstrated a significant Gap Junctional Intercellular Communication (GJIC) enhancement upon treatment with 5 × 10(-5) mol/L for 48 hours. The effects of LNG were most noticeable in HESCs rather than in HEGCs.
Name Type Language
NORGESTREL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NORGESTREL COMPONENT OF OVRAL
Common Name English
norgestrel [INN]
Common Name English
NORGESTREL [HSDB]
Common Name English
NORGESTREL [USP-RS]
Common Name English
WY-3707
Code English
SH-70850
Code English
Norgestrel [WHO-DD]
Common Name English
OVRAL COMPONENT NORGESTREL
Common Name English
NORGESTREL [USAN]
Common Name English
FH-122A
Code English
NORGESTREL [EP MONOGRAPH]
Common Name English
NORGESTREL [JAN]
Common Name English
18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(±)-
Common Name English
NORGESTREL [USP MONOGRAPH]
Common Name English
NORGESTREL [MI]
Common Name English
(±)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE
Common Name English
NORGESTREL [ORANGE BOOK]
Common Name English
CRYSELLE COMPONENT NORGESTREL
Common Name English
DL-NORGESTREL
Common Name English
SH-850
Code English
NORGESTREL [MART.]
Common Name English
NSC-757251
Code English
NORGESTREL COMPONENT OF CRYSELLE
Common Name English
NORGESTREL [VANDF]
Common Name English
OVRETTE
Brand Name English
Classification Tree Code System Code
WHO-VATC QG03FA10
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
WHO-VATC QG03FB01
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
WHO-VATC QG03AA06
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
NCI_THESAURUS C776
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
WHO-ATC G03FA10
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
WHO-ATC G03AA06
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
LIVERTOX 699
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
WHO-ATC G03FB01
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
Code System Code Type Description
PUBCHEM
13109
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
MERCK INDEX
m8063
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
NORGESTREL
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
CHEBI
7630
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
RS_ITEM_NUM
1472000
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
EVMPD
SUB09371MIG
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
MESH
D009644
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
SMS_ID
100000092602
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
INN
2157
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
CAS
6533-00-2
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
NCI_THESAURUS
C703
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
DRUG BANK
DB09389
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
HSDB
3595
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
DAILYMED
3J8Q1747Z2
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
FDA UNII
3J8Q1747Z2
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
NSC
757251
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107797
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
RXCUI
7518
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
229-433-5
Created by admin on Fri Dec 15 15:26:36 GMT 2023 , Edited by admin on Fri Dec 15 15:26:36 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of NORGESTREL
PARENT (METABOLITE ACTIVE)
NORGESTIMATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966